Abstract
Alzheimer disease (ADa) is the most common form of senile dementia, and it is characterized pathologically by decreased brain mass. An important problem to inhibiting β-secretase, is to cross the blood-brain barrier (BBB) using drugs not derived from proteins and thus more efficient to design drugs to treat Alzheimers disease. In this sense, quantitative structure-activity relationships (QSAR) could play an important role in studying these β-secretase inhibitors. QSAR models are necessary in order to guide the β-secretase synthesis. In the present work, we firstly revised two servers like ChEMBL or PDB to obtain databases of β-secretase inhibitors. Next, we review previous works based on 2D-QSAR, 3DQSAR, CoMFA, CoMSIA and Docking techniques, which studied different compounds to find out the structural requirements. Last, we carried out new QSAR studies using Artificial Neural Network (ANN) method and the software Modes- Lab in order to understand the essential structural requirement for binding with receptor for β-secretase inhibitors.
Keywords: QSAR, CoMSIA, COMFA, docking, topological indices, β-secretase inhibitors, alzheimer's disease (AD), Romuald.Bellmann@i-med.ac.at, Lipinski Parameters,, Transport Protein, Glycerol Acetate ion, Glycerol, Protein transport hidrolase, triphloroethol, Lamarckian Genetic Algorithm
Current Bioinformatics
Title: Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Volume: 6 Issue: 1
Author(s): Francisco Prado-Prado, Manuel Escobar-Cubiella and Xerardo Garcia-Mera
Affiliation:
Keywords: QSAR, CoMSIA, COMFA, docking, topological indices, β-secretase inhibitors, alzheimer's disease (AD), Romuald.Bellmann@i-med.ac.at, Lipinski Parameters,, Transport Protein, Glycerol Acetate ion, Glycerol, Protein transport hidrolase, triphloroethol, Lamarckian Genetic Algorithm
Abstract: Alzheimer disease (ADa) is the most common form of senile dementia, and it is characterized pathologically by decreased brain mass. An important problem to inhibiting β-secretase, is to cross the blood-brain barrier (BBB) using drugs not derived from proteins and thus more efficient to design drugs to treat Alzheimers disease. In this sense, quantitative structure-activity relationships (QSAR) could play an important role in studying these β-secretase inhibitors. QSAR models are necessary in order to guide the β-secretase synthesis. In the present work, we firstly revised two servers like ChEMBL or PDB to obtain databases of β-secretase inhibitors. Next, we review previous works based on 2D-QSAR, 3DQSAR, CoMFA, CoMSIA and Docking techniques, which studied different compounds to find out the structural requirements. Last, we carried out new QSAR studies using Artificial Neural Network (ANN) method and the software Modes- Lab in order to understand the essential structural requirement for binding with receptor for β-secretase inhibitors.
Export Options
About this article
Cite this article as:
Prado-Prado Francisco, Escobar-Cubiella Manuel and Garcia-Mera Xerardo, Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors, Current Bioinformatics 2011; 6 (1) . https://dx.doi.org/10.2174/157489311795222428
DOI https://dx.doi.org/10.2174/157489311795222428 |
Print ISSN 1574-8936 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-392X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain
Current Alzheimer Research Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimers Disease, and its Relationship with Cognitive Impairment
Current Alzheimer Research Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The Ambivalence of Early Diagnosis – Returning Results in Current Alzheimer Research
Current Alzheimer Research Transendothelial Migration of Monocytes: The Underlying Molecular Mechanisms and Consequences of HIV-1 Infection
Current HIV Research Glucocorticoid Excess Induces Accumulation of Cardiac Glycogen and Triglyceride: Suggested Role for AMPK
Current Pharmaceutical Design Insulin-Like Growth Factor-1, a Potential Predicative Biomarker for Postoperative Delirium Among Elderly Patients with Open Abdominal Surgery
Current Pharmaceutical Design Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Current Topics in Medicinal Chemistry Progression of Mild Cognitive Impairment to Alzheimers or Vascular Dementia Versus Normative Aging Among Elderly Chinese
Current Alzheimer Research Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine Integrating Care for Older Adults with Cognitive Impairment
Current Alzheimer Research Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Current Neuropharmacology Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India
Current Vascular Pharmacology Editorial (Thematic Issue: Ceramics, Nanotubes, Advanced Materials: Theoretical and Experimental Structure-Property Relationships: Part V)
Current Physical Chemistry Advances in the Discovery of Novel Positive Allosteric Modulators of the α7 Nicotinic Acetylcholine Receptor
Recent Patents on CNS Drug Discovery (Discontinued) Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design Oxidative/Nitrosative Brain Damage in Stress: Possible Target for Neuropsychopharmacological Drugs
Current Medicinal Chemistry - Central Nervous System Agents